How to Price Cancer Drugs
Executive Summary
Competitors and payors will force drug companies to justify their drug prices based on value delivered. With oncology as an example, we show a way to rate multiple factors to arrive at an overall clinical value--and then how to translate this value into an appropriate price for the new product. But the pricing assumptions will also change how products are launched.
You may also be interested in...
NitroMed's BiDil Pricing: Test for a Whole Class of New Companies
After putting two generics together and then getting the product approved for a new indication, NitroMed priced its new drug above expectations. But will the old-style pricing strategy hold up in a managed care world?
Where Drug Firms Go Wrong in International Drug Pricing
Mispricing in Europe--pricing the new therapy too high compared to perceived incremental value than the older therapy--has been a key reason that new classes of drugs haven't achieved their volume objectives. Successful follow-on classes like statins and proton pump inhibitors have kept their European prices relatively close to the costs of the previous therapies; less successful ones, like the glitazones, have not.
As Quantity Of Cannabis IND Applications Grows, US FDA Has ‘Quality Considerations’ Guidance
Research targeting botanicals generally, as well as cannabis, as potential APIs is increasing, a factor in CDER’s publication of cannabis trials guidance, the FDA’s Norman Birenbaum says in an interview.